西藏民族大学医学院/西藏民族大学高原相关疾病分子遗传机制与干预研究省级重点实验室/ 环境与疾病相关基因研究高校重点实验室,咸阳 712082
Received:15 July 2024,
Revised:2024-10-26,
Accepted:28 October 2024,
Published:28 December 2025
移动端阅览
本文
Mao Yaqi,Jin Zichong,Hu Ye,et al.Research advances in ventricular hypertrophy[J].Journal of Chongqing Medical University,2025,50(12):1695-1701.
本文 DOI: 10.13406/j.cnki.cyxb.003737.
Mao Yaqi,Jin Zichong,Hu Ye,et al.Research advances in ventricular hypertrophy[J].Journal of Chongqing Medical University,2025,50(12):1695-1701. DOI: 10.13406/j.cnki.cyxb.003737.
心血管疾病是一种世界范围内广泛存在的疾病,严重影响患者的健康状况和生活质量。近年来对心室肥厚的研究强调了其作为心脏结构和功能改变的一个重要指标,这种改变与多种心血管风险因素紧密相关,特别是高血压、遗传倾向和肥胖。心室肥厚是导致心血管系统发病和死亡的主要危险因素,且高血压和肥胖是心脏重塑和功能障碍的主要影响因素,导致左心室肥厚和心力衰竭。心电图(electrocardiogram,ECG)、超声心动图(echocardiography,ECHO)是当前诊断心室肥厚的主要手段。治疗策略包括药物治疗、控制血压、肥胖等,目的是减轻心脏负担、逆转心脏肥厚和改善心脏功能。本文梳理了心血管疾病伴发心室肥厚的文献,就心室肥厚相关研究动态、趋势和关键问题进行分析,综述心室肥厚的流行病学、病因、诊断及其治疗方案等,为该病的防治提供理论依据。
Cardiovascular disease is a widespread disease around the world,seriously affecting the health status of quality of life of patients. In recent years,the studies on ventricular hypertrophy have highlighted its role as a key indicator for changes in cardiac structure and function,and such changes are closely associated with various cardiovascular risk factors,especially hypertension,genetic predisposition,and obesity. Ventricular hypertrophy is a major risk factor for cardiovascular morbidity and mortality,and hypertension and obesity are major risk factors for heart remodeling and dysfunction,which may lead to left ventricular hypertrophy and heart failure. electrocardiogram and echocardiography are currently the main methods for the diagnosis of ventricular hypertrophy,and treatment strategies include pharmacotherapy and control of blood pressure and obesity,with the purposes of reducing heart burden,reversing heart hypertrophy,and improving cardiac function. By reviewing the articles on cardiovascular diseases with ventricular hypertrophy,this article analyzes the current status,trends,and key issues of the research on ventricular hypertrophy and elaborates on the epidemiology,etiology,diagnosis,and treatment of ventricular hypertrophy,in order to provide a theoretical basis for diagnosis and treatment.
Mensah GA , Fuster V , Roth GA . A heart-healthy and stroke-free world:using data to inform global action [J ] . J Am Coll Cardiol , 2023 , 82 ( 25 ): 2343 - 2349 .
刘明波 , 何新叶 , 杨晓红 , 等 . 《中国心血管健康与疾病报告2023》要点解读 [J ] . 中国心血管杂志 , 2024 , 29 ( 4 ): 305 - 324 .
Liu MB , He XY , Yang XH , et al . Interpretation of report on cardiovascular health and diseases in China 2023 [J ] . Chin J Cardiovasc Med , 2024 , 29 ( 4 ): 305 - 324 .
Bazgir F , Nau J , Nakhaei-Rad S , et al . The microenvironment of the pathogenesis of cardiac hypertrophy [J ] . Cells , 2023 , 12 ( 13 ): 1780 .
Martin TG , Juarros MA , Leinwand LA . Regression of cardiac hypertrophy in health and disease:mechanisms and therapeutic potential [J ] . Nat Rev Cardiol , 2023 , 20 ( 5 ): 347 - 363 .
Pena E , Brito J , El Alam S , et al . Oxidative stress,kinase activity and inflammatory implications in right ventricular hypertrophy and heart failure under hypobaric hypoxia [J ] . Int J Mol Sci , 2020 , 21 ( 17 ): 6421 .
Tadic M , Cuspidi C , Marwick TH . Phenotyping the hypertensive heart [J ] . Eur Heart J , 2022 , 43 ( 38 ): 3794 - 3810 .
Maron BJ , Gardin JM , Flack JM , et al . Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults [J ] . Circulation , 1995 , 92 ( 4 ): 785 - 789 .
Rouskas P , Zegkos T , Ntelios D , et al . Prevalence,characteristics,and natural history of apical phenotype in a large cohort of patients with hypertrophic cardiomyopathy [J ] . Hellenike Kardiologike Epitheorese , 2023 , 73 : 8 - 15 .
Sciacqua A , Cimellaro A , Mancuso L , et al . Different patterns of left ventricular hypertrophy in metabolically healthy and insulin-resistant obese subjects [J ] . Nutrients , 2020 , 12 ( 2 ): 412 .
Maki KC , Wilcox ML , Dicklin MR , et al . Left ventricular mass regression,all-cause and cardiovascular mortality in chronic kidney disease:a meta-analysis [J ] . BMC Nephrol , 2022 , 23 ( 1 ): 34 .
Flores K , Siques P , Brito J , et al . AMPK and the challenge of treating hypoxic pulmonary hypertension [J ] . Int J Mol Sci , 2022 , 23 ( 11 ): 6205 .
Oldfield CJ , Duhamel TA , Dhalla NS . Mechanisms for the transition from physiological to pathological cardiac hypertrophy [J ] . Can J Physiol Pharmacol , 2020 , 98 ( 2 ): 74 - 84 .
Shimizu I , Minamino T . Physiological and pathological cardiac hypertrophy [J ] . J Mol Cell Cardiol , 2016 , 97 : 245 - 262 .
Lin HR , Zhu YQ , Zheng CK , et al . Antihypertrophic memory after regression of exercise-induced physiological myocardial hypertrophy is mediated by the long noncoding RNA Mhrt779 [J ] . Circulation , 2021 , 143 ( 23 ): 2277 - 2292 .
Bei YH , Huang ZZ , Feng X , et al . Lymphangiogenesis contributes to exercise-induced physiological cardiac growth [J ] . J Sport Health Sci , 2022 , 11 ( 4 ): 466 - 478 .
Schulman-Geltzer EB , Fulghum KL , Singhal RA , et al . Cardiac mitochondrial metabolism during pregnancy and the postpartum period [J ] . Am J Physiol Heart Circ Physiol , 2024 , 326 ( 5 ): 1324 - 1335 .
Fulghum KL , Smith JB , Chariker J , et al . Metabolic signatures of pregnancy-induced cardiac growth [J ] . Am J Physiol Heart Circ Physiol , 2022 , 323 ( 1 ): 146 - 164 .
Yang YJ , Kurian J , Schena G , et al . Cardiac remodeling during pregnancy with metabolic syndrome:prologue of pathological remodeling [J ] . Circulation , 2021 , 143 ( 7 ): 699 - 712 .
Bourque K , Hawey C , Jones-Tabah J , et al . Measuring hypertrophy in neonatal rat primary cardiomyocytes and human iPSC-derived cardiomyocytes [J ] . Methods , 2022 , 203 : 447 - 464 .
Shi L , Tan YZ , Zheng WY , et al . CTRP3 alleviates mitochondrial dysfunction and oxidative stress injury in pathological cardiac hypertrophy by activating UPRmt via the SIRT1/ATF5 axis [J ] . Cell Death Discov , 2024 , 10 ( 1 ): 53 .
Burban A , Pucyło S , Sikora A , et al . Hypertrophic cardiomyopathy versus storage diseases with myocardial involvement [J ] . Int J Mol Sci , 2023 , 24 ( 17 ): 13239 .
Marian AJ . Molecular genetic basis of hypertrophic cardiomyopathy [J ] . Circ Res , 2021 , 128 ( 10 ): 1533 - 1553 .
Keramida K , Lazaros G , Nihoyannopoulos P . Right ventricular involvement in hypertrophic cardiomyopathy:Patterns and implications [J ] . Hell J Cardiol , 2020 , 61 ( 1 ): 3 - 8 .
Zheng CY , Wang X , Tang HS , et al . Habitation altitude and left ventricular diastolic function:a population-based study [J ] . J Am Heart Assoc , 2021 , 10 ( 3 ): e018079 .
Parodi JB , Ramchandani R , Zhou ZE , et al . A systematic review of electrocardiographic changes in healthy high-altitude populations [J ] . Trends Cardiovasc Med , 2023 , 33 ( 5 ): 309 - 315 .
Bilo G , Caravita S , Torlasco C , et al . Blood pressure at high altitude:physiology and clinical implications [J ] . Kardiol Pol , 2019 , 77 ( 6 ): 596 - 603 .
Sun YQ , Ma JF , Yan TJ , et al . Evaluation of cardiac index and right ventricular hypertrophy index in rats under a chronic hypoxic environment at high altitude [J ] . Heliyon , 2024 , 10 ( 3 ): e25229 .
Papoušek F , Sedmera D , Neckář J , et al . Left ventricular function and remodelling in rats exposed stepwise up to extreme chronic intermittent hypoxia [J ] . Respir Physiol Neurobiol , 2020 , 282 : 103526 .
Lv JL , Liu Y , Yan YK , et al . Relationship between left ventricular hypertrophy and diabetes is likely bidirectional:a temporality analysis [J ] . J Am Heart Assoc , 2023 , 12 ( 6 ): e028219 .
Fan YJ , Yan ZP , Li TT , et al . Primordial drivers of diabetes heart disease:comprehensive insights into insulin resistance [J ] . Diabetes Metab J , 2024 , 48 ( 1 ): 19 - 36 .
Chuang SM , Liu SC , Leung CH , et al . High left ventricular mass associated with increased risk of incident diabetes [J ] . Sci Rep , 2024 , 14 ( 1 ): 250 .
Lei XT , Pu DL , Shan G , et al . Atorvastatin ameliorated myocardial fibrosis by inhibiting oxidative stress and modulating macrophage polarization in diabetic cardiomyopathy [J ] . World J Diabetes , 2024 , 15 ( 6 ): 1070 - 1073 .
Beslika E , Leite-Moreira A , de Windt LJ , et al . Large animal models of pressure overload-induced cardiac left ventricular hypertrophy to study remodelling of the human heart with aortic stenosis [J ] . Cardiovasc Res , 2024 , 120 ( 5 ): 461 - 475 .
Sager P , Rusch A , Weber L , et al . ECG left ventricular hypertrophy in aortic stenosis:Relationship with cardiac structure,invasive hemodynamics,and long-term mortality [J ] . Clin Cardiol , 2024 , 47 ( 1 ): e24155 .
Maqbool S , Shafiq S , Ali S , et al . Left ventricular hypertrophy (LVH) and left ventricular geometric patterns in patients with chronic kidney disease(CKD) stage 2-5 with preserved ejection fraction(EF):a systematic review to explore CKD stage-wise LVH patterns [J ] . Curr Probl Cardiol , 2023 , 48 ( 4 ): 101590 .
Zhang TY , An DA , Fang Y , et al . Assessment of the prognostic value of MRI left ventricular global function index(LVGFI) in patients with end-stage renal disease under maintenance dialysis [J ] . J Magn Reson Imaging , 2024 , 59 ( 6 ): 2275 - 2286 .
Kaesler N , Babler A , Floege J , et al . Cardiac remodeling in chronic kidney disease [J ] . Toxins , 2020 , 12 ( 3 ): 161 .
Talib A , Roebroek YGM , Paulus GF , et al . Left ventricular geometrical changes in severely obese adolescents:prevalence,determinants,and clinical implications [J ] . Pediatr Cardiol , 2021 , 42 ( 2 ): 331 - 339 .
Murdolo G , Angeli F , Reboldi G , et al . Left ventricular hypertrophy and obesity: only a matter of fat? [J ] . High Blood Press Cardiovasc Prev , 2015 , 22 : 29 - 41 .
曹亚船 , 豆吉娟 , 马亚萍 , 等 . 肥胖儿童脂质代谢与左心室肥厚及左心室重构的相关性 [J ] . 中国儿童保健杂志 , 2023 , 31 ( 7 ): 809 - 812 .
Cao YC , Dou JJ , Ma YP , et al . Correlation of lipid metabolism with left ventricular hypertrophy and left ventricular remodeling in obese children [J ] . Chin J Child Health Care , 2023 , 31 ( 7 ): 809 - 812 .
del Gaudio F , Liu DL , Andaloussi Mäe M , et al . Left ventricular hypertrophy and metabolic resetting in the Notch3-deficient adult mouse heart [J ] . Sci Rep , 2023 , 13 ( 1 ): 15022 .
Gao SY , Yang QC , Peng Y , et al . SIRT6 regulates obesity-induced oxidative stress via ENDOG/SOD2 signaling in the heart [J ] . Cell Biol Toxicol , 2023 , 39 ( 4 ): 1489 - 1507 .
Grabowski K , Herlan L , Witten A , et al . Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension [J ] . Hypertens Res , 2022 , 45 ( 2 ): 292 - 307 .
Oikonomou E , Theofilis P , Mpahara A , et al . Diagnostic performance of electrocardiographic criteria in echocardiographic diagnosis of different patterns of left ventricular hypertrophy [J ] . Ann Noninvasive Electrocardiol , 2020 , 25 ( 3 ): e12728 .
Zhang W , Zhou YW , Bai B , et al . Consistency of left ventricular hypertrophy diagnosed by electrocardiography and echocardiography:the Northern Shanghai Study [J ] . Clin Interv Aging , 2019 , 14 : 549 - 556 .
Jian ZN , Wang XP , Zhang JZ , et al . Diagnosis of left ventricular hypertrophy using convolutional neural network [J ] . BMC Med Inform Decis Mak , 2020 , 20 ( 1 ): 243 .
中国医师协会心血管内科医师分会心力衰竭学组 , 心衰中心心肌病专家委员会 . 左心室肥厚诊断和治疗临床路径中国专家共识2023 [J ] . 中国循环杂志 , 2024 , 39 ( 1 ): 17 - 28 .
Heart Failure Center , Cardiomyopathy Expert Committee of Heart Failure Group , Cardiovascular Medicine Branch of Chinese Medical Doctor Association . Clinical pathway of diagnosis and treatment of left ventricular hypertrophy:Chinese expert consensus 2023 [J ] . Chin Circ J , 2024 , 39 ( 1 ): 17 - 28 .
Moura B , Aimo A , Al-Mohammad A , et al . Diagnosis and management of patients with left ventricular hypertrophy:Role of multimodality cardiac imaging. A scientific statement of the Heart Failure Association of the European Society of Cardiology [J ] . Eur J Heart Fail , 2023 , 25 ( 9 ): 1493 - 1506 .
Bula K , Bisaga J , Feret B , et al . Electro- and echocardiographic features of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy [J ] . Ann Noninvasive Electrocardiol , 2022 , 27 ( 5 ): e12992 .
Marian AJ , Braunwald E . Hypertrophic cardiomyopathy:genetics,pathogenesis,clinical manifestations,diagnosis,and therapy [J ] . Circ Res , 2017 , 121 ( 7 ): 749 - 770 .
张志杰 , 曹 剑 , 王怡宁 , 等 . 高原性心脏病40例心脏磁共振表现分析 [J ] . 实用医学影像杂志 , 2022 , 23 ( 6 ): 541 - 545 .
Zhang ZJ , Cao J , Wang YN , et al . Cardiovascular magnetic resonance manifestations of high altitude heart disease [J ] . J Pract Med Imag , 2022 , 23 ( 6 ): 541 - 545 .
Wan JJ , Zhang Z , Wu CN , et al . Astragaloside Ⅳ derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456 [J ] . Signal Transduct Target Ther , 2023 , 8 ( 1 ): 414 .
Moreira-Costa L , Tavares-Silva M , Almeida-Coelho J , et al . Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction [J ] . Eur J Pharmacol , 2024 , 966 : 176336 .
Hu JJ , Zhou YD . Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension:a meta-analysis of randomized trials [J ] . Blood Press , 2023 , 32 ( 1 ): 2242501 .
Soliman EZ , Mills KT . Exploring the relationship between intensive blood pressure lowering,left ventricular hypertrophy,and cardiovascular outcomes [J ] . Hypertension , 2023 , 80 ( 9 ): 1843 - 1844 .
Yamamoto E , Usuku H , Sueta D , et al . Efficacy and safety of esaxerenone in hypertensive patients with left ventricular hypertrophy (ESES-LVH) study:a multicenter,open-label,prospective,interventional study [J ] . Adv Ther , 2024 , 41 ( 3 ): 1284 - 1303 .
Wang MY , Liu XQ , Jiang TT , et al . Roxadustat versus erythropoietin:the comparison of efficacy in reversing ventricular remodeling in dialysis patients with anaemia [J ] . Int J Med Sci , 2024 , 21 ( 4 ): 703 - 713 .
Hu N , Lv N , Chen YQ . Treatment with sacubitril/valsartan effectively manages hypertension and ameliorates left ventricular hypertrophy in hemodialysis patients [J ] . Blood Purif , 2024 , 53 ( 8 ): 657 - 664 .
Dihoum A , Brown AJ , McCrimmon RJ , et al . Dapagliflozin,inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy [J ] . BMC Cardiovasc Disord , 2024 , 24 ( 1 ): 356 .
Vanderpool RR , Gorelova A , Ma YR , et al . Reversal of right ventricular hypertrophy and dysfunction by prostacyclin in a rat model of severe pulmonary arterial hypertension [J ] . Int J Mol Sci , 2022 , 23 ( 10 ): 5426 .
Li MH , Liu X , Xie YL , et al . Sodium butyrate alleviates right ventricular hypertrophy in pulmonary arterial hypertension by inhibiting H19 and affecting the activation of let-7g-5p/IGF1 receptor/ERK [J ] . Eur J Pharmacol , 2024 , 965 : 176315 .
Han YW , Li SD , Zhang ZY , et al . Bawei Chenxiang Wan ameliorates right ventricular hypertrophy in rats with high altitude heart disease by SIRT3-HIF1α-PDK/PDH signaling pathway improving fatty acid and glucose metabolism [J ] . BMC Complement Med Ther , 2024 , 24 ( 1 ): 190 .
Jiang XL , Shao MY , Liu X , et al . Reversible treatment of pressure overload-induced left ventricular hypertrophy through Drd5 nucleic acid delivery mediated by functional polyaminoglycoside [J ] . Adv Sci , 2021 , 8 ( 5 ): 2003706 .
Lewis MI , Shapiro S , Oudiz RJ , et al . The ALPHA phase 1 study:pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells [J ] . EBioMedicine , 2024 , 100 : 104900 .
梁博深 , 尹红科 , 王 磊 , 等 . 苍艾挥发油通过调节氧化应激反应对高原心肌肥厚大鼠的治疗作用 [J ] . 四川大学学报(医学版) , 2024 , 55 ( 6 ): 1485 - 1493 .
Liang BS , Yin HK , Wang L , et al . Therapeutic effect of Cang-ai volatile oil on high-altitude rats with cardiac hypertrophy through modulation of oxidative stress response [J ] . J Sichuan Univ Med Sci , 2024 , 55 ( 6 ): 1485 - 1493 .
0
Views
6
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
